Millennium: The Takeda Oncology Company Release: Study Analysis Identifies Potential Biomarkers of VELCADE (Bortezomib) Activity in Patients with Relapsed Mantle Cell Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE® (bortezomib) in patients with relapsed/refractory mantle cell lymphoma (MCL). The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL. The results add to the body of data supporting the potential usefulness of biomarkers in predicting outcome of MCL and predicting responsiveness to single agent VELCADE. The study is published in the July issue of Leukemia & Lymphoma.